US Approves AstraZeneca’s IMFINZI Regimen for Muscle-Invasive Bladder Cancer

The approved regimen combines neoadjuvant IMFINZI (durvalumab) with enfortumab vedotin-ejfv, followed by adjuvant IMFINZI after radical cystectomy, for adults with muscle-invasive bladder cancer.